title: Too little mTORC1 activity injures the liver.
abstract: Obesity promotes chronic activation of mTORC1 and is a known risk factor for hepatic injury, inflammation, and carcinogenesis. In this issue, Umemura et al. (2014) demonstrate that a persistent reduction in hepatic mTORC1 activity also promotes cell damage and inflammation and sensitizes the liver to cancer development.
authors.affiliation: Oncology Research Unit, Pfizer Worldwide Research and Development, 10646/CB4 Science Center Drive, San Diego, CA 92121, USA. Electronic address: robert.abraham@pfizer.com.
authors.forename: Robert T
authors.initials: RT
authors.lastname: Abraham
mesh_terms: D000818:Animals; D006801:Humans; D007249:Inflammation; D008099:Liver / Q000187:drug effects*; D008297:Male; D000076222:Mechanistic Target of Rapamycin Complex 1; D046912:Multiprotein Complexes / Q000378:metabolism*; D020123:Sirolimus / Q000633:toxicity*; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D046912:Multiprotein Complexes; D000076222:Mechanistic Target of Rapamycin Complex 1; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus